Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 7% Improvement Relative Risk ARDS -9% ICU time -34% Hospitalization time -37% Favipiravir  Al Mutair et al.  ICU PATIENTS Is very late treatment with favipiravir beneficial for COVID-19? Retrospective 538 patients in Saudi Arabia (April 2020 - March 2021) Study compares with various, results vs. placebo may differ Longer ICU admission (p=0.001) and hospitalization (p=0.001) Al Mutair et al., J. Infection and Pub.., Feb 2022 Favors favipiravir Favors various

Overview of Clinical Outcome and Therapeutic Effectiveness of Favipiravir in Patients with COVID-19 Admitted to Intensive Care Unit, Riyadh, Saudi Arabia

Al Mutair et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013
Feb 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 269 favipiravir ICU patients in Saudi Arabia and 269 matched controls receiving different treatments, showing no significant difference.
This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.
risk of death, 7.0% lower, RR 0.93, p = 0.49, treatment 119 of 269 (44.2%), control 128 of 269 (47.6%), NNT 30.
risk of ARDS, 8.6% higher, RR 1.09, p = 0.63, treatment 76 of 269 (28.3%), control 70 of 269 (26.0%), severe ARDS.
ICU time, 33.7% higher, relative time 1.34, p = 0.001, treatment 269, control 269.
hospitalization time, 36.6% higher, relative time 1.37, p = 0.001, treatment 269, control 269.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Al Mutair et al., 15 Feb 2022, retrospective, Saudi Arabia, peer-reviewed, 14 authors, study period April 2020 - March 2021, this trial compares with another treatment - results may be better when compared to placebo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia
Abbas Al Mutair, Jinan Shamou, Saad Alhumaid, Laila Layqah, Gasmelseed Y Ahmed, Koritala Thoyaja, Mohammed Al Mohaini, Sana Almahmoud, Mazin Barry, Amjad Khan, Kuldeep Dhama, Lamiaa Hamad Al-Jamea, Alxeander Woodman, Ali A Rabaan
Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.01.013
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Al-Wathinani, Increased Emergency Calls during the COVID-19 Pandemic in Saudi Arabia: A National Retrospective Study, Healthcare, doi:10.3390/healthcare9010014
Alharthy, Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study, Journal of epidemiology and global health, doi:10.2991/jegh.k.200928.001
Almoosa, Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study, J Infect Public Health, doi:10.1016/j.jiph.2021.08.022
Alsofayan, Althunayyan, Khan, Hakawi, Assiri, Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study, Journal of infection and public health, doi:10.1016/j.jiph.2020.05.026
Argenziano, Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series, Bmj, doi:10.1136/bmj.m1996
Bai, Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014, Clin Infect Dis, doi:10.1093/cid/ciw571
Bartoletti, Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, doi:10.1016/j.cmi.2020.09.014
Beigel, Remdesivir for the Treatment of Covid-19 -Final Report, The New England journal of medicine, doi:10.1056/NEJMoa2007764
Bosaeed, Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19, BMJ Open, doi:10.1136/bmjopen-2020-047495
Cai, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering, doi:10.1016/j.eng.2020.03.007
Cao, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Chen, Chao, Lai, Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients, The Journal of infection, doi:10.1016/j.jinf.2020.12.005
Chen, Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, medRxiv, doi:10.1101/2020.03.17.20037432
Choy, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104786
Chu, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, doi:10.1136/thorax.2003.012658
Cummings, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, Lancet, doi:10.1016/S0140-6736(20)31189-2
Delang, Abdelnabi, Neyts, Favipiravir as a potential countermeasure against neglected and emerging RNA viruses, Antiviral Res, doi:10.1016/j.antiviral.2018.03.003
Fiolet, Guihur, Rebeaud, Mulot, Peiffer-Smadja et al., Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, doi:10.1016/j.cmi.2020.08.022
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proceedings of the Japan Academy. Series B, Physical and biological sciences, doi:10.2183/pjab.93.027
Gavriatopoulou, Emerging treatment strategies for COVID-19 infection, Clinical and experimental medicine, doi:10.1007/s10238-020-00671-y
Guan, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Horby, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2021436
Hu, Risk Factors Associated With Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China, Clin Infect Dis, doi:10.1093/cid/ciaa539
Huang, Pranata, Lim, Oehadian, Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Therapeutic advances in respiratory disease, doi:10.1177/1753466620937175
J O U R N, a l P r e -p r o o f international review of thoracic diseases, doi:10.1159/000507940
Khamis, Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.008
Khorram-Manesh, Goniewicz, Hertelendy, Dulebenets, Handbook of Disaster and Emergency Management
Ko, Arguments in favour of remdesivir for treating SARS-CoV-2 infections, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105933
Kocayiğit, Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19, Journal of Clinical Pharmacy and Therapeutics
Koritala, A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy
Liang, A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir, European journal of medicinal chemistry, doi:10.1016/j.ejmech.2020.112527
Lighter, Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission, Clin Infect Dis
Liu, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci, doi:10.1007/s11427-020-1643-8
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Mahévas, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, Bmj
Mortaz, Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra, International immunopharmacology, doi:10.1016/j.intimp.2021.107407
Oestereich, Lüdtke, Wurr, Rieger, Muñoz-Fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, doi:10.1016/j.antiviral.2014.02.014
Perazzolo, Zhu, Lin, Nguyen, Ho, Systems and Clinical Pharmacology of COVID-19 Therapeutic Candidates: A Clinical and Translational Medicine Perspective, J Pharm Sci, doi:10.1016/j.xphs.2020.11.019
Prompetchara, Ketloy, Palaga, Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic, Asian Pac J Allergy Immunol, doi:10.12932/ap-200220-0772
Qin, Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19), Clin Infect Dis, doi:10.1093/cid/ciaa248
Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis, Virol J, doi:10.1186/s12985-020-01412-z
Sinha, Balayla, Hydroxychloroquine and COVID-19, Postgraduate Medical Journal, doi:10.1136/postgradmedj-2020-137785
Solaymani-Dodaran, Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, International immunopharmacology, doi:10.1016/j.intimp.2021.107522
Totura, Bavari, Broad-spectrum coronavirus antiviral drug discovery, Expert opinion on drug discovery, doi:10.1080/17460441.2019.1581171
Van Eeden, Hogg, Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies, Respiration, doi:10.1159/000502261
Vidali, D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review, ERJ Open Res, doi:10.1183/23120541.00260-2020
Wang, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, Jama, doi:10.1001/jama.2020.1585
Wang, Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report, Annals of internal medicine, doi:10.7326/L20-0354
Wang, Zhou, Yang, Xia, Hu et al., Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, Jama, doi:10.1001/jama.2020.2648
Wu, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Xiong, Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study, BMC infectious diseases, doi:10.1186/s12879-020-05452-2
Yang, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/s2213-2600(20)30079-5
Ye, Wang, Mao, The pathogenesis and treatment of the `Cytokine Storm' in COVID-19, J Infect, doi:10.1016/j.jinf.2020.03.037
Yu, Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis, J Thromb Thrombolysis, doi:10.1007/s11239-020-02171-y
Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/s0140-6736(20)30566-3
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop